Reddy K, S., A.K, K., Bhava B.S, S., P, S., P, A., E, V. (2013). Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats. Iranian Journal of Pharmaceutical Sciences, 9(2), 87-101.
Sainath Reddy K; Kaleem A.K; Sharvana Bhava B.S; Satish P; Aravind P; Venkateshwarlu E. "Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats". Iranian Journal of Pharmaceutical Sciences, 9, 2, 2013, 87-101.
Reddy K, S., A.K, K., Bhava B.S, S., P, S., P, A., E, V. (2013). 'Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats', Iranian Journal of Pharmaceutical Sciences, 9(2), pp. 87-101.
Reddy K, S., A.K, K., Bhava B.S, S., P, S., P, A., E, V. Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats. Iranian Journal of Pharmaceutical Sciences, 2013; 9(2): 87-101.
Lornoxicam Alone and with Selegiline Improves the Neuroprotective Effect and Cognition in Scopolamine Induced Neurodegeneration and Cognitive Impairment in Rats
Department of Pharmacology, Vaagdevi College of pharmacy, Warangal, INDIA.
Abstract
Alzheimer is a progressive neurodegenerative disorder in which Oxidative stress plays a major role. The present study was designed to investigate Neuroprotective effect of Lornoxicam, Selegiline and co-administration of both drugs in Scopolamine induced cognitive impairment and neurodegeneration. Scopolamine (1.4mg/kg) was administered intraperitoniallyin male Wistar rats. Rectangular maze performance test was used to assess the memory performance test. Various biochemical parameters such as Catalase, 1, 1-diphenyl-2- picrylhydrazine (DPPH), Thiobarbituric acid reactive substances(TBARS), reduced glutathione(GSH) and acetylcholine esterase (AchE) were also assessed. IntraperitonialScopolamine results marked memory impairment and oxidative damage. Sub-acute treatment with Lornoxicam (1.3mg/kg, p.o) and Selegiline (0.49mg/kg, p.o) and co-administration of these two drugs for 8 days significantly attenuated scopolamine induced oxidative damage and neurodegeneration. Besides, Lornoxicam, Selegiline and co-administration of both significantly reversed Scopolamine administered increase in acetylcholine esterase activity. Present study indicates protective effect of Lornoxicam, Selegiline and co-administration of both drugs against Scopolamine induced cognitive impairment and oxidative damage. The memory enhancing capacity of the drugs was very significant when compared with disease control (P <0.001).